Cargando…

Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma

Glioblastomas are characterized by amplification of EGFR. Approximately half of tumors with EGFR over-expression also express a constitutively active ligand independent EGFR variant III (EGFRvIII). While current treatments emphasize surgery followed by radiation and chemotherapy with Temozolomide (T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Velpula, Kiran K., Guda, Maheedhara R., Sahu, Kamlesh, Tuszynski, Jack, Asuthkar, Swapna, Bach, Sarah E., Lathia, Justin D., Tsung, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482605/ https://www.ncbi.nlm.nih.gov/pubmed/28410193 http://dx.doi.org/10.18632/oncotarget.16767

Ejemplares similares

GLUT1 and TUBB4 in Glioblastoma Could be Efficacious Targets
por: Guda, Maheedhara R., et al.
Publicado: (2019)

Targeting RGS4 Ablates Glioblastoma Proliferation
por: Guda, Maheedhara R., et al.
Publicado: (2020)

Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism
por: Guda, Maheedhara R., et al.
Publicado: (2022)

Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020)

Immunopathology of galectin-3: an increasingly promising target in COVID-19
por: Caniglia, John L., et al.
Publicado: (2020)

A potential role for Galectin-3 inhibitors in the treatment of COVID-19
por: Caniglia, John L., et al.
Publicado: (2020)

Beyond glucose: alternative sources of energy in glioblastoma
por: Caniglia, John L., et al.
Publicado: (2021)

The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005)

Targeting FHL2 for EGFRvIII-positive glioblastoma
por: Sun, Lili, et al.
Publicado: (2018)

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells
por: Vengoji, Raghupathy, et al.
Publicado: (2019)

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)

B7-H3 in Medulloblastoma-Derived Exosomes; A Novel Tumorigenic Role
por: Purvis, Ian J., et al.
Publicado: (2020)

Methylation regulates HEY1 expression in glioblastoma
por: Tsung, Andrew J., et al.
Publicado: (2017)

EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016)

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
por: Struve, Nina, et al.
Publicado: (2020)

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
por: Hoogstrate, Youri, et al.
Publicado: (2021)

EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma
por: NOZAWA, Takanori, et al.
Publicado: (2019)

GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
por: Choi, Justin, et al.
Publicado: (2022)

PAD Inhibitors as a Potential Treatment for SARS-CoV-2 Immunothrombosis
por: Elliott, Willie, et al.
Publicado: (2021)

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells—EGFRvIII Appears as a Weak Oncogene
por: Włodarczyk, Aneta, et al.
Publicado: (2022)

Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis
por: Purvis, Ian J., et al.
Publicado: (2019)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells
por: Struve, Nina, et al.
Publicado: (2015)

Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010)

EGFRvIII Promotes the Proneural–Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-κB/ALDH1A3 Axis
por: Shi, Zhong-Fang, et al.
Publicado: (2023)

A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII
por: Trembath, Dimitri G, et al.
Publicado: (2007)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023)

Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
por: Xu, Wen, et al.
Publicado: (2015)

Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma
por: Babu, Ranjith, et al.
Publicado: (2012)

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
por: Shen, Ying, et al.
Publicado: (2015)

Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme
por: Newman, Jennifer P., et al.
Publicado: (2017)

Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells
por: Zhang, Xingmei, et al.
Publicado: (2018)

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery
por: Bao, Xuhui, et al.
Publicado: (2016)

EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment
por: Keller, Stefanie, et al.
Publicado: (2017)

Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
por: Ren, Pei-pei, et al.
Publicado: (2017)

Guanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro
por: Lan, Qing, et al.
Publicado: (2016)

Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma
por: Durgin, Joseph S., et al.
Publicado: (2021)

IGFBP3 induced by the TGF-β/EGFRvIII transactivation contributes to the malignant phenotype of glioblastoma
por: Zhang, Xuehua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uihjc1uv6ntg6e3d83e0sd2qa8